Compare RDHL & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDHL | BDRX |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.0M |
| IPO Year | N/A | N/A |
| Metric | RDHL | BDRX |
|---|---|---|
| Price | $1.13 | $2.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 66.1K | ★ 2.8M |
| Earning Date | 09-05-2025 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,550,000.00 | N/A |
| Revenue This Year | $381.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 157.62 | N/A |
| 52 Week Low | $1.01 | $2.55 |
| 52 Week High | $7.00 | $92.00 |
| Indicator | RDHL | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 38.99 |
| Support Level | $1.10 | $4.55 |
| Resistance Level | $1.23 | $7.22 |
| Average True Range (ATR) | 0.05 | 1.49 |
| MACD | 0.00 | -0.28 |
| Stochastic Oscillator | 28.25 | 1.25 |
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.